强直性脊柱炎患者使用依那西普致结核性眼内炎1例并文献回顾
|
摘要
目的报告1例强直性脊柱炎的患者在接受抗肿瘤坏死因子α(tumor necrosis factor alpha,TNF-α)治疗后出现双眼葡萄膜炎的病例。方法行结核相关检查并给予抗结核及抗炎对症支持治疗。结果患者症状明显好转,预后良好。结论广大医务工作者在开始抗TNF-α治疗前,应对患者进行全面检查排除结核感染。有潜伏性和陈旧性结核感染的患者应在行抗TNF-α治疗前接受预防性抗结核治疗,并严密随访观察至抗TNF-α治疗终止3个月后。
Objective To report a case with ankylosing spondylitis(AS) who had been administered anti-tumor necrosis of factor alpha(TNF-α) agent, and developed as uveitis, and which was finally diagnosed as tuberculous endophthalmitis.Methods The anti-tuberculosis therapy and anti-inflammation therapy were performed.Results The patient's symptoms improved obviously and the prognosis was good.Conclusion Patients should be checked to exclude tuberculosis infection before beginning anti-TNF-α treatment. Patients with both latent and obsolete tuberculosis infections should be given a prophylactic anti-tuberculosis treatment prior to anti-TNF-α therapy,and should be followed 3 months after anti-TNF-α therapy has been discontinued.
Objective To report a case with ankylosing spondylitis(AS) who had been administered anti-tumor necrosis of factor alpha(TNF-α) agent, and developed as uveitis, and which was finally diagnosed as tuberculous endophthalmitis.Methods The anti-tuberculosis therapy and anti-inflammation therapy were performed.Results The patient's symptoms improved obviously and the prognosis was good.Conclusion Patients should be checked to exclude tuberculosis infection before beginning anti-TNF-α treatment. Patients with both latent and obsolete tuberculosis infections should be given a prophylactic anti-tuberculosis treatment prior to anti-TNF-α therapy,and should be followed 3 months after anti-TNF-α therapy has been discontinued.
引文
[1] Maxwell LJ,Zochling J,Boonen A, et al.TNF-alpha inhibitors for ankylosing spondylitis[J]. Cochrane Database Syst Rev,2005, 4(4): D5468
[2] Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort[J]. Ann Rheum Dis,2018, 77(1): 63-69
[3] Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010, 69(3): 522-528
[4] Sampaio-Barros PD,van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: Are they different from RA?[J]. Best Pract Res Clin Rheumatol,2014, 28(5): 747-763
[5] Rubbert-Roth A, Atzeni F, Masala IF, et al. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?[J]. Autoimmu Rev,2018, 17(1): 24-28
[6] Fonollosa A, Segura A, Giralt J, et al. Tuberculous uveitis after treatment with etanercept[J]. Graefes Arch Clin Exp Ophthalmol,2007, 245(9): 1397-1399
[7] Huo R, Romanelli P. Etanercept Therapy for Psoriasis in a Patient with Active Pulmonary Tuberculosis[J]. Am J Clin Dermatol,2010, 11(1): 39-40
[8] Lie E, Lindstr?m U, Zverkova-Sandstr?m T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register[J]. Ann Rheum Dis,2017, 76(9): 1515-1521
[9] Azuma N, Morimoto M, Tsubota N, et al. Tuberculous peritonitis during etanercept therapy for rheumatoid arthritis[J]. Nihon Rinsho Meneki Gakkai Kaishi,2011, 34(6): 501-509
[10] Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy[J]. Clin Exp Rheumatol,2003, 21(4): 526
[11] Choi SW,Ahn JJ,Hwang YT, et al. A case of tuberculous arthritis following the use of etanercept[J]. Korean J Intern Med,2009, 24(4): 397-401
[12] Shibata S, Shono E, Nishimagi E, et al. A patient with urinary tract tuberculosis during treatment with etanercept[J]. Am J Case Rep,2015, 16(8): 341-346
[13] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志,2013, 17(8): 508-512
[14] Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs[J]. Am J Ther,2001, 8(2): 123-143
[15] Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge[J]. Clin Exp Rheumatol,2002, 20(6 Suppl 28): S152-S157
[16] Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis[J].Expert Opin Drug Saf,2016, 15(sup1): 35-54
[17] Bonovas S, Fiorino G, Allocca M, et al. Biologic Therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis[J]. Clin Gastroenterol Hepatol,2016,14(10): 1385-1397
[18] Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology[J]. Infect Immun,2001, 69(3): 1847-1855
[19] Roach DR,Bean AG,Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection[J]. J Immunol,2002, 168(9): 4620-4627
[20] Cao BL, Qasem A, Sharp RC, et al. Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-α inhibitors(Anti-TNFα)[J]. World J Gastroenterol,2018, 24(25): 2764-2775
[21] Lie E, Lindstr?m U, Zverkova-Sandstr?m T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register[J]. Ann Rheuma Dis,2017, 76(9): 1515-1521
[22] Wendling D,Joshi A,Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database[J]. Curr Med Res Opin,2014, 30(12): 2515-2521
[23] Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review[J]. Expert Opin Drug Saf,2015, 14(4): 571-582
[2] Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort[J]. Ann Rheum Dis,2018, 77(1): 63-69
[3] Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010, 69(3): 522-528
[4] Sampaio-Barros PD,van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: Are they different from RA?[J]. Best Pract Res Clin Rheumatol,2014, 28(5): 747-763
[5] Rubbert-Roth A, Atzeni F, Masala IF, et al. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?[J]. Autoimmu Rev,2018, 17(1): 24-28
[6] Fonollosa A, Segura A, Giralt J, et al. Tuberculous uveitis after treatment with etanercept[J]. Graefes Arch Clin Exp Ophthalmol,2007, 245(9): 1397-1399
[7] Huo R, Romanelli P. Etanercept Therapy for Psoriasis in a Patient with Active Pulmonary Tuberculosis[J]. Am J Clin Dermatol,2010, 11(1): 39-40
[8] Lie E, Lindstr?m U, Zverkova-Sandstr?m T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register[J]. Ann Rheum Dis,2017, 76(9): 1515-1521
[9] Azuma N, Morimoto M, Tsubota N, et al. Tuberculous peritonitis during etanercept therapy for rheumatoid arthritis[J]. Nihon Rinsho Meneki Gakkai Kaishi,2011, 34(6): 501-509
[10] Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy[J]. Clin Exp Rheumatol,2003, 21(4): 526
[11] Choi SW,Ahn JJ,Hwang YT, et al. A case of tuberculous arthritis following the use of etanercept[J]. Korean J Intern Med,2009, 24(4): 397-401
[12] Shibata S, Shono E, Nishimagi E, et al. A patient with urinary tract tuberculosis during treatment with etanercept[J]. Am J Case Rep,2015, 16(8): 341-346
[13] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志,2013, 17(8): 508-512
[14] Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs[J]. Am J Ther,2001, 8(2): 123-143
[15] Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge[J]. Clin Exp Rheumatol,2002, 20(6 Suppl 28): S152-S157
[16] Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis[J].Expert Opin Drug Saf,2016, 15(sup1): 35-54
[17] Bonovas S, Fiorino G, Allocca M, et al. Biologic Therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis[J]. Clin Gastroenterol Hepatol,2016,14(10): 1385-1397
[18] Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology[J]. Infect Immun,2001, 69(3): 1847-1855
[19] Roach DR,Bean AG,Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection[J]. J Immunol,2002, 168(9): 4620-4627
[20] Cao BL, Qasem A, Sharp RC, et al. Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-α inhibitors(Anti-TNFα)[J]. World J Gastroenterol,2018, 24(25): 2764-2775
[21] Lie E, Lindstr?m U, Zverkova-Sandstr?m T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register[J]. Ann Rheuma Dis,2017, 76(9): 1515-1521
[22] Wendling D,Joshi A,Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database[J]. Curr Med Res Opin,2014, 30(12): 2515-2521
[23] Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review[J]. Expert Opin Drug Saf,2015, 14(4): 571-582